Skip to main content
SpringerLink
Log in

Prophylaxis against hypomagnesaemia induced by cis-platinum combination chemotherapy

  • Short Communication
  • Cis-Platinum Hypomagnesaemia
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Hypomagnesaemia is recognised as a feature of the renal tubular defect produced by cis-platinum therapy for cancer. It may be sufficiently severe to cause tetany and grand mal fits. Attempts to correct established hypomagnesaemia whilst continuing cis-platinum therapy have not proved satisfactory. We have therefore investigated the prophylactic addition of 3 g magnesium sulphate to the high-dose platinum regimen with which metastatic malignant teratoma is treated in this unit. Serum magnesium levels have been measured in eight patients treated in this way and compared with those recorded for eight matched patients previously treated without routine magnesium supplements. Magnesium levels fell into the range frequently associated with clinical manifestation in five of the eight unsupplemented patients and only one of those given magnesium prophylactically. Mean serum magnesium levels were significantly higher in the supplemented group when compared usingthe paired t-test (P<0.01). Routine supplementation with intravenous magnesium sulphate is a simple and effective way of preventing symptomatic hypomagnesaemia associated with cis-platinum therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Carney SL, Wong NLM, Quamme GA, Dirks JH (1980) Effect of magnesium deficiency on renal magnesium and calcium transport in the rat. J Clin Invest 65: 180

    Google Scholar 

  2. Condit PT, Chanes RE, Joel W (1969) Renal toxicity of methotrexate. Cancer 23: 126

    Google Scholar 

  3. Connor TB, Toskes P, Mahaffey J, Martin LG, Williams JB, Walser M (1972) Parathyroid function during chronic magnesium deficiency. Johns Hopkins Med J 131: 100

    Google Scholar 

  4. Duarte CG (1968) Effects of ethacrynic acid and furosemide on urinary calcium, phosphate and magnesium. Metabolism 17: 867

    Google Scholar 

  5. Freedman DB, Shannon M, Dandona P, Prentice HG, Hoffbrand AV (1982) Hypoparathyroidism and hypocalcaemia during treatment for acute leukaemia. Br Med J 284: 700

    Google Scholar 

  6. Gonzales-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS (1977) The renal pathology in clinical trials of cis-platinum (II) diammine-dichloride. Cancer 39: 1362

    Google Scholar 

  7. Hamed IA, Lindemann RD (1978) Dysphagia and vertical nystagmus in magnesium deficiency. Ann Intern Med 89: 222

    Google Scholar 

  8. Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH (1977) High-dose cis-platinum diammine dichloride. Amelioration of renal toxicity by mannitol diuresis. Cancer 39: 1372

    Google Scholar 

  9. Martin HE (1969) Clinical magnesium deficiency. Ann NY Acad Sci 162: 891

    Google Scholar 

  10. Massry SG, Coburn JW (1973) The hormonal and non-hormonal control of renal excretion of calcium and magnesium. Nephron 10: 66

    Google Scholar 

  11. Newlands ES, Begent RHJ, Kaye SB, Rustin GJS, Bagshawe KD (1980) Chemotherapy of advanced malignant teratomas. Br J Cancer 42: 378

    Google Scholar 

  12. Schilsky RL, Anderson T (1979) Hypomagnesaemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 90: 929

    Google Scholar 

  13. Somjen G, Hilmy M, Stephen CR (1966) Failure to anaesthetise human subjects by intravenous administration of magnesium sulphate. J Pharmacol Exp Ther 154: 652

    Google Scholar 

  14. Suh SM, Tashjian AH Jr, Matsuo N, Parkinson DK, Fraser D (1973) Pathogenesis of hypocalcaemia in primary hypomagnesaemia: normal end-organ responsiveness to parathyroid hormone, impaired parathyroid gland function. J Clin Invest 52: 153

    Google Scholar 

  15. Wacker WEC, Parish AF (1968) Magnesium metabolism. N Engl J Med 278: 658, 712

    Google Scholar 

  16. Wilks JB (1960) Determination of metabolites in blood serum by atomic absorption spectrophotometry. II. Magnesium. Spectrochim Acta 16: 273

    Google Scholar 

  17. Williams CJ, Whitehouse JMA (1979) cis-Platinum: a new anticancer agent. Br Med J I: 1689

    Google Scholar 

  18. Young RR, Bradley WG, Adams RD (1981) Approach to clinical myology. In: Harrison's Principles of internal medicine, 9th edn. McGraw-Hill, Tokyo, p 2041

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Charing Cross Hospital Medical School, Charing Cross Hospital, Fulham Palace Road, W.6., London, Great Britain

    V. M. Macaulay, R. H. J. Begent & E. S. Newlands

  2. Department of Medicine, Charing Cross Hospital Medical School, Charing Cross Hospital, Fulham Palace Road, W.6., London, Great Britain

    M. E. Phillips

Authors
  1. V. M. Macaulay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. H. J. Begent
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. E. Phillips
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. S. Newlands
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Macaulay, V.M., Begent, R.H.J., Phillips, M.E. et al. Prophylaxis against hypomagnesaemia induced by cis-platinum combination chemotherapy. Cancer Chemother. Pharmacol. 9, 179–181 (1982). https://doi.org/10.1007/BF00257749

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00257749

Keywords

Search

Navigation